PTO/SB/26 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A "PRIOR" PATENT	98204.00024
In re Application of: Robert H. Zimmer	
Application No.: 10/825,472	
Filed: April 15, 2004	
For: Compositions and Methods for Enhanced Pharmacological Activity of Compositions Comprising Peptide Drug Substances	
The owner*, immuPharma SA except a provided below, the terminal part of the statutory term of any patent granted on the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond here objected on the statutory term prior patent No. 5,908,900. as the term of said prior patent is defined in 35 U.S. C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforcable to enfy for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee;	
is held unenforceable; is found invalid by a court of competent jurisdiction; is studing disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a recreamination certificate; is relative is relative in vinative in terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful liste statements and the file so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may looperatize the validity of the application or any patient issued thereon.	
2. The undersigned is an attorney or agent of record. Reg. No. 54,566	
/Bryan Zerhusen/	August 15, 2007
Signature	Date
Bryan Zerhusen	
Typed or printed name	
	860-275-6735
	Telephone Number
Terminal disclaimer fee under 37 CFR 1.20(d) included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement_under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner) Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or ratio is breatly by the public which is to find each by the USE70. This objection of confidentably is governed by 35 U.S. C. 12 and S7 St. List 1.32 to 1